melanocortin_receptor_agonist

PT-141

INN: bremelanotide CAS: 189691-06-3 MW: 1025.2 g/mol (free base) Formula C50H68N14O10

Key takeaways

  • PT-141 / bremelanotide is FDA-approved as Vyleesi (NDA 210557, 2019-06-21) for one narrow population only — acquired generalised hypoactive sexual desire disorder in premenopausal women — and is unapproved everywhere else (no EMA, no MHRA, no Health Canada, no PMDA, no NMPA, no MFDS, no GRLS, no WHO EML).
  • The community-dominant use case — male libido via subcutaneous off-label injection — has no completed Phase 3 trial. The only randomised male data are the abandoned intranasal-route programme (Diamond 2004, Rosen 2004) halted in 2008 over a hypertension signal, and the sildenafil-non-responder trial (Safarinejad 2008) which now carries a 2023 published Expression of Concern.
  • Science scores differ sharply by claim: female HSDD A/65 (two positive Phase 3 RCTs, modest effect size, 40% nausea, 18% all-cause discontinuation); male sexual function C/20 (no Phase 3, withdrawn route programme, EoC-flagged paper). Same molecule, same dose, different evidence.
  • Community Score A/80. ~22 years of continuous presence (Palatin intranasal era ~2003 → 2008 BP hold → 2019 Vyleesi approval → 2020–2026 grey-market injectable phase). Vyleesi-derived 1.75 mg SC, ≥45 min lead time, ≤1/24 h, ≤8/month is the canonical protocol across telehealth clinics, biohacker write-ups, and forum FAQs. ~40% non-responder rate reported in men (Jay Campbell aggregated via Greenfield).
  • WADA 2026: not named on the Prohibited List, not on the Monitoring Program. Off-label use outside the athlete's jurisdiction-of-approval defaults to S0 (Non-Approved Substances), prohibited at all times. DoD/OPSS flags PT-141 on its high-risk peptide ingredient guidance. TGA: Schedule 4 (prescription-only).

Identity Calibration

PT-141 / bremelanotide is a cyclic heptapeptide melanocortin agonist (Ac-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH); cyclic via Asp–Lys lactam) designed by Palatin Technologies in the late 1990s. Community discourse routinely conflates it with melanotan-II, with which it shares Palatin-era lineage but differs structurally and clinically. The relationship is:

  • Melanotan-I (afamelanotide) — linear α-MSH analogue, originated at the University of Arizona (Hadley/Hruby programme); commercialised by Clinuvel for erythropoietic protoporphyria.
  • Melanotan-II — cyclic lactam α-MSH analogue; produced unexpected sexual-arousal and penile-erection effects in male volunteers during tanning studies in the 1990s, redirecting industrial interest. Palatin licensed melanotan-II from Competitive Technologies and discontinued development in 2000. Carries reported case literature on persistent naevus darkening, new melanocytic lesions, and melanoma diagnoses in heavy chronic users.
  • PT-141 / bremelanotide — synthesised by Palatin as a likely metabolite of melanotan-II, differing by a free carboxyl terminus rather than an amide. Same broad melanocortin receptor agonism class; same rank-order potency (MC1R > MC4R > MC3R > MC5R > MC2R); narrower characterised use case (FDA-approved for premenopausal HSDD, dose-capped at 8/month).

Calibration consequence: community claims drawn from the melanotan-II case literature (severe chronic-use hyperpigmentation, melanoma risk, persistent darkening) are not automatically valid for bremelanotide at on-label dose-capped exposure, but are relevant for off-label chronic-use exposure outside the label’s 8/month ceiling. The encyclopedia treats the molecules as related-but-distinct: the safety record of melanotan-II is the relevant scientific precedent for off-label heavy use of bremelanotide; it is not the safety record of on-label bremelanotide.

Route adds a second axis of identity ambiguity: intranasal bremelanotide (Palatin’s original investigational route) was abandoned in 2008 over a dose-dependent BP signal. Community-channel “compounded intranasal spray” marketed by Formulate Rx, Inner Balance, and others is the same molecule but a route the originator specifically discarded for safety reasons, not a benign convenience alternative to subcutaneous administration. Mirror flags appear in identity_warnings (two_molecule_confusion, route_changes_claim).

1. Identity

FieldValueSource
INNbremelanotide[Regulatory document — FDA NDA 210557 Vyleesi label, June 2019]
Research codesPT-141; BMT; BMT-801 (current Palatin obesity programme code)[Press release — Palatin Technologies 2019, 2024–2025; not peer-reviewed]
CAS (free base)189691-06-3[Academic secondary source — PubChem CID 9941379; Sigma-Aldrich SML2756]
CAS (acetate salt)1607799-13-2[Academic secondary source — Sigma-Aldrich SML2756; note the CAS 32780-32-8 cited in some task briefs is not corroborated by primary chemistry registries]
Molecular formula (free base)C₅₀H₆₈N₁₄O₁₀[Regulatory document — FDA Vyleesi label §11]
Molecular formula (acetate)C₅₀H₆₈N₁₄O₁₀ · xCH₃COOH (1 ≤ x ≤ 2)[Regulatory document — FDA Vyleesi label §11]
Molecular weight (free base)1025.2 g/mol[Regulatory document — FDA Vyleesi label §11]
SequenceAc-Nle-cyclo-(Asp-His-D-Phe-Arg-Trp-Lys-OH); cyclic heptapeptide, Asp–Lys lactam[Regulatory document — FDA Vyleesi label §11]
ClassMelanocortin receptor agonist (non-selective); rank order MC1R > MC4R > MC3R > MC5R > MC2R (negligible MC2R)[Regulatory document — FDA Vyleesi label §12.1]
Brand name (FDA-approved)Vyleesi (1.75 mg/0.3 mL prefilled autoinjector)[Regulatory document — FDA NDA 210557, 2019-06-21]
Mean terminal half-life (SC)≈ 2.7 h[Regulatory document — FDA Vyleesi Multidisciplinary Review §12.3]
Tmax (SC)≈ 1.0 h[Regulatory document — FDA Vyleesi Multidisciplinary Review §12.3]
PubChem CID9941379[Academic secondary source — PubChem]
OriginatorPalatin Technologies (Cranbury, NJ); chemistry rights via Competitive Technologies licence[Press release — Palatin historical SEC filings; not peer-reviewed]
Current US marketing authorisation holderCosette Pharmaceuticals (acquired Vyleesi from AMAG/Covis transaction chain)[Press release — Palatin/Cosette 2023; not peer-reviewed]

2. History and Development

The lineage traces to the α-melanocyte-stimulating hormone (α-MSH) structure–activity programme at the University of Arizona in the 1980s–1990s, headed by Mac E. Hadley and Victor J. Hruby. The programme generated melanotan-I (afamelanotide; later commercialised by Clinuvel for erythropoietic protoporphyria) and melanotan-II [Peer-reviewed historical review — Hadley 1998 Pharm Biotechnol 11:575]. During human tanning studies, melanotan-II produced unexpected sexual-arousal and penile-erection effects in male volunteers, redirecting industrial interest toward sexual dysfunction indications [Peer-reviewed historical review — Hadley 2005 Peptides 26:1687].

Competitive Technologies licensed melanotan-II to Palatin Technologies. Palatin discontinued melanotan-II development in 2000 and synthesised bremelanotide — chemically described as a likely metabolite of melanotan-II, differing by a free carboxyl terminus rather than an amide [Press release — Palatin SEC filings; not peer-reviewed]. A contractual dispute was settled in 2008; Palatin retained bremelanotide rights and returned melanotan-II rights [Press release — Palatin SEC; not peer-reviewed].

Initial clinical development targeted male erectile dysfunction via an intranasal formulation. Phase 1/2 work in 2003–2007 (Diamond 2004, Rosen 2004, Safarinejad 2008) showed pharmacodynamic erectile responses but documented a clinically meaningful blood-pressure signal at the doses required by the intranasal route. Palatin’s intranasal ED programme — partnered with King Pharmaceuticals from 2004 — was placed on clinical hold by FDA in 2007 and terminated in 2008 over the hypertension signal [Press release — Palatin SEC 2008; not peer-reviewed].

Palatin pivoted to subcutaneous administration and to hypoactive sexual desire disorder (HSDD) in premenopausal women, conducting a Phase 2b dose-ranging study (Clayton 2016 Women’s Health, doses 0.75/1.25/1.75 mg SC) and the two pivotal Phase 3 RECONNECT trials (Studies 301 and 302; NCT02333071 and NCT02338960). AMAG Pharmaceuticals acquired the North American rights in February 2017 and submitted the NDA. FDA approved Vyleesi (NDA 210557) on 21 June 2019 for acquired generalised HSDD in premenopausal women [Regulatory document — FDA NDA approval letter, 2019-06-21].

Commercialisation rights moved from AMAG (acquired by Covis Pharma 2020) to Palatin (regaining rights July 2023) and then to Cosette Pharmaceuticals, which currently markets Vyleesi in the United States. Palatin separately re-initiated melanocortin obesity development with the BMT-801 Phase 2 study (bremelanotide co-administered with tirzepatide; NCT06565611), which reported primary-endpoint achievement on 2025-03-31 ⚠️ industry-funded [Press release — Palatin Technologies; not peer-reviewed]. This is a separate, ongoing programme distinct from the 2008-era hypertension-driven discontinuation.

3. Mechanism of Action

Demonstrated in humans

  • Bremelanotide is a non-selective melanocortin receptor agonist; the FDA label states the rank-order potency profile as MC1R > MC4R > MC3R > MC5R > MC2R, with binding to MC1R and MC4R most relevant at therapeutic dose levels [Regulatory document — FDA Vyleesi label §12.1].
  • The label states explicitly: “The mechanism by which VYLEESI improves HSDD in women is unknown” — the molecule’s receptor pharmacology is characterised but the human neurocircuitry responsible for the clinical effect is not established to regulatory satisfaction [Regulatory document — FDA Vyleesi label §12.1].
  • Documented human pharmacodynamic effects: transient increase in SBP (~6 mmHg peak), DBP (~3 mmHg peak) 2–4 h post-dose, with concurrent ~5 bpm reduction in heart rate, returning to baseline within 12 h [Regulatory document — FDA Vyleesi label §5.1, §12.2].
  • Bremelanotide slows gastric emptying in humans, producing the labelled drug-interaction warning for orally administered concomitant drugs including naltrexone [Regulatory document — FDA Vyleesi label §7].
  • Focal hyperpigmentation in ~1% of subjects at on-label dosing (≤8/month); 38% with daily dosing for 8 days; consistent with MC1R engagement on melanocytes [Regulatory document — FDA Vyleesi label §5.2].

Proposed / preclinical

  • MC4R-mediated central pathway: bremelanotide activates MC4R-expressing neurons in the hypothalamic paraventricular nucleus (PVN) and medial preoptic area (mPOA); downstream signalling is Gαs–cAMP–PKA [Peer-reviewed preclinical review — Pfaus 2007 J Sex Med 4 Suppl 4:269].
  • Female rat appetitive sexual behaviour: subcutaneous bremelanotide selectively increases solicitations, hops, and darts without altering lordosis or pacing; effect reproduced by intra-mPOA infusion [Peer-reviewed preclinical study — Pfaus 2004 PNAS 101:10201].
  • Male rat erectile pathway: melanocortin agonists drive penile erection via PVN MC4R-expressing oxytocin neurons projecting to spinal autonomic nuclei. ⚠️ 🔴 Specific peripheral-pathway elaboration in this circuit relies substantially on the Argiolas/Melis group (Cagliari) [Peer-reviewed preclinical study — Argiolas & Melis 2005 Eur J Pharmacol; Sanna et al. 2011 — single-group dependency for some downstream nitric-oxide-paraventricular mechanism claims].
  • MC3R, MC5R contribution: roles not established as causal for sexual-behaviour effects; MC5R is largely associated with exocrine gland function [Peer-reviewed preclinical study — Chen 1997 Cell].
  • MC1R cutaneous engagement: drives eumelanin synthesis in melanocytes — the proposed mechanism of focal hyperpigmentation reported clinically.

Not demonstrated / common overclaims

  • “Spontaneous arousal” framing as proven CNS mechanism. The community framing of PT-141 as a “desire-driven, not blood-flow-driven” agent (Huberman Lab 2024-04-01; Ben Greenfield via Dexa.ai) is mechanistically plausible from rodent appetitive-behaviour models but is not what the FDA label characterises — the label states the human mechanism is unknown.
  • “PT-141 increases endogenous oxytocin” as basis for stacking with exogenous oxytocin. The claim (Aliyah Moore via Hone Health) is preclinical-only at the rat PVN MC4R → oxytocin-neuron level; no controlled human study has measured plasma oxytocin response to bremelanotide.
  • “PT-141 normalises mood via norepinephrine” — preclinical receptor-level inference, not a clinical effect characterised in any trial.

4. Regulatory Status

4.1 Drug-regulatory status

  • FDA: Vyleesi (NDA 210557), approved 2019-06-21 for premenopausal women with acquired generalised HSDD; subcutaneous 1.75 mg/0.3 mL autoinjector; no REMS [Regulatory document — FDA NDA 210557 approval letter and Multidisciplinary Review].
  • FDA 503A compounding status: Bremelanotide was not on the agenda of the 2024-10-29 PCAC meeting (which addressed ibutamoren mesylate, L-theanine, ipamorelin-related substances, kisspeptin-10) nor the 2024-12-04 PCAC meeting (AOD-9604, CJC-1295-related, thymosin alpha-1) [Regulatory document — FDA PCAC meeting notices and transcripts, 2024]. Because bremelanotide is the subject of an FDA-approved drug (Vyleesi), it can in principle be compounded under the “component of an FDA-approved drug” pathway of §503A(b)(1)(A)(i)(I); it has not been placed on the Category 1 or Category 2 interim 503A bulk drug substances list and was not the subject of a PCAC vote as of 2026-05-17. Status is materially different from Ipamorelin (PCAC 0–12–1 against, October 2024) or Epitalon (PCAC review scheduled July 2026).
  • EMA: No marketing authorisation. Vyleesi has never been authorised in the EEA. Palatin obtained pre-Phase-3 EMA scientific advice via a 2013–2014 European licensing-option process but no Centralised Procedure application was filed. EPAR database returns no entry [Regulatory document — EMA EPAR search, accessed 2026-05-17].
  • MHRA (UK): Not authorised.
  • Health Canada: Not authorised; no Notice of Compliance.
  • TGA (Australia): Not on the Australian Register of Therapeutic Goods. Bremelanotide is Schedule 4 (Prescription Only Medicine) under the Therapeutic Goods (Poisons Standard — October 2025) Instrument 2025, accessible via compounding-pharmacy supply on prescription [Regulatory document — TGA SUSMP October 2025]. This is materially less restrictive than the TGA treatment of melanotan-I and melanotan-II, which have been subject to direct enforcement.
  • PMDA (Japan): Not authorised.
  • NMPA (China): Not authorised.
  • MFDS (South Korea): Not authorised.
  • GRLS (Russia): No registration identified.
  • WHO Model List of Essential Medicines: Not listed (2023/2025 editions).

4.2 Anti-doping status

  • WADA 2026 Prohibited List (in force 2026-01-01): Bremelanotide is not listed by name in any S-section (S0–S9, P1) and is not on the 2026 Monitoring Program [Anti-doping document — WADA 2026 Prohibited List and Monitoring Program]. Bremelanotide does not share the structural class of α-MSH peptide hormones covered under S2.
  • S0 catch-all: Where bremelanotide is not approved for therapeutic use in the athlete’s jurisdiction, it falls under S0 (Non-Approved Substances), prohibited at all times for any pharmacological substance not addressed by other List sections and without current approval by any governmental regulatory health authority for human therapeutic use. In jurisdictions where Vyleesi is approved (US), bremelanotide is an approved substance; whether S0 applies in those cases is the subject of standing WADA interpretive guidance — athletes are routinely directed to apply for a TUE if therapeutic use is anticipated.
  • TUE eligibility: standard TUE pathway available where therapeutic indication (premenopausal HSDD) is documented.
  • NCAA banned-drug-class list (2025–26): Not enumerated; falls under NCAA’s non-approved-substances catch-all only if used to enhance performance; clinical sexual-medicine use unlikely to trigger NCAA categories.
  • DoD / OPSS Prohibited Dietary Supplement Ingredients list: Bremelanotide / PT-141 is flagged on the OPSS high-risk ingredient list as an unapproved drug-class peptide present in some products marketed to service members [Anti-doping document — DoD OPSS ingredient guidance, accessed 2026-05-17].
  • Global DRO: Cross-checked 2026-05-17. Database does not return a bremelanotide / PT-141 specific entry in the standard search; users are referred to general prohibited-list logic.
  • Detection: LC-HRMS / LC-MS/MS in plasma and urine; plasma half-life ≈ 2.7 h; urinary detection windows on the order of 24–72 hours post single SC dose per WADA-accredited laboratory method papers [Peer-reviewed analytical method — Esposito et al., Drug Test Anal, bremelanotide LC-MS methodology, 2018–2021 range].
  • Notable sanctions / precedents: no high-profile elite-athlete sanction specifically for bremelanotide identified as of 2026-05-17.

4.3 Last regulatory review

Last regulatory review: 2026-05-17

5. Formulations and Routes

  • FDA-approved: Vyleesi 1.75 mg / 0.3 mL subcutaneous solution in a single-dose prefilled autoinjector for abdomen or thigh administration; inactive ingredients glycerin 2.5%, water for injection, HCl/NaOH for pH adjustment [Regulatory document — FDA Vyleesi label §3, §11].
  • Intranasal (investigational, discontinued): used in early Palatin Phase 1/2 studies (10–20 mg) for male ED and female sexual arousal disorder; discontinued in 2008 following dose-dependent BP elevations observed in Phase 2 [Peer-reviewed human study — Diamond 2004 Int J Impot Res 16:51; Press release — Palatin 2008; not peer-reviewed].
  • Subcutaneous (investigational, prior to Vyleesi): Diamond/Rosen 2004 dose-finding studies in healthy men and PDE5-inadequate-response ED patients [Peer-reviewed human study — Rosen 2004 Int J Impot Res 16:135].
  • Compounded subcutaneous injection (off-label): appears in physician-supervised and grey-market settings for male ED, libido enhancement, and post-menopausal HSDD. Not FDA-approved as a compounded product. Quality, purity, and concentration are not subject to NDA-grade controls. Flagged as off-label.
  • Compounded intranasal spray / sublingual troches: present in commercial compounded channels. Not FDA-approved; documented BP-elevation risk contributed to abandonment of the intranasal route by the originator. Flagged as off-label and as carrying the route-specific historical safety signal.

6. Preclinical Evidence

All claims in this section are preclinical.

  • Female rat appetitive sexual behaviour models: Pfaus et al. (Concordia) demonstrated that subcutaneous bremelanotide and direct mPOA infusion selectively increase solicitational behaviours (hops, darts, female-initiated approach) in oestrogen-primed ovariectomised rats without altering lordosis or pacing [Peer-reviewed preclinical study — Pfaus 2004 PNAS 101:10201; Pfaus 2007 J Sex Med 4 Suppl 4:269]. Independent replication from the Giuliano/Gelez Paris group [Peer-reviewed preclinical study — Rössler et al. 2006 Pharmacol Biochem Behav 85:514 (melanotan-II)].
  • Male rodent erection assays: yawning-and-penile-erection paradigm; bremelanotide and structurally related melanocortin agonists induce penile erection via PVN MC4R neurons projecting to spinal autonomic outflow. ⚠️ 🔴 The Cagliari group (Argiolas, Melis, Sanna, Succu) is the dominant single source for the oxytocin/NO-paraventricular mechanistic detail [Peer-reviewed preclinical study — Argiolas & Melis multiple publications; single-group dependency on peripheral-cascade specifics].
  • MC4R knockout mice: loss of MC4R produces hyperphagia and obesity (Huszar 1997 Cell); preclinical sexual-behaviour phenotype in MC4R-null mice supports a role for MC4R in melanocortinergic facilitation of mounting and intromission [Peer-reviewed preclinical study — Van der Ploeg 2002 PNAS].
  • cAMP signalling: heterologous-expression assays (HEK293) confirm Gαs–cAMP coupling with EC50s consistent with the FDA-stated potency rank order [Peer-reviewed preclinical pharmacology — IUPHAR/BPS GtoPdb melanocortin family pages].
  • Cardiovascular preclinical: centrally-mediated pressor effects on the sympathetic outflow demonstrated in rodent telemetry studies provide a mechanistic substrate for the human BP signal [Peer-reviewed preclinical study — Greenfield 2009 N Engl J Med corollary on MC4R sympathetic activation].

7. Clinical Evidence

7.1 Cochrane / systematic reviews

No dedicated Cochrane Systematic Review for bremelanotide as of 2026-05-17. The most recent broad non-Cochrane synthesis is Anand et al. 2025 (PMID 40543759 — systematic review and meta-analysis of treatments for female sexual desire, arousal, and orgasmic dysfunction), which reports that bremelanotide improved total FSFI, FSFI-Desire, FSFI-Arousal subscales versus placebo, and reduced distress [Peer-reviewed meta-analysis — Anand 2025].

7.2 Randomized controlled trials

Pivotal Phase 3 — Female HSDD (RECONNECT 301 & 302). ⚠️ Industry-funded (Palatin/AMAG); Kingsberg et al. 2019 Obstet Gynecol 134(5):899–908, PMID 31599840.

  • Design: two identical 24-week double-blind placebo-controlled multicentre RCTs; 1,247 premenopausal women with acquired generalised HSDD; bremelanotide 1.75 mg SC as-needed vs placebo; 52-week open-label extension.
  • Co-primary endpoints (FDA-agreed): change from baseline to end of core phase in (i) FSFI-Desire domain score (range 1.2–6.0) and (ii) FSDS-DAO Item 13 (“how often bothered by low sexual desire”, 0–4 scale).
  • Results (pooled): bremelanotide produced statistically significant improvements over placebo on both co-primary endpoints (p<0.001). FSFI-D improvement ~0.30–0.35 points over placebo. FSDS-DAO-13 improvement ~0.30 over placebo. Number of satisfying sexual events (SSE) did not separate from placebo statistically.
  • Discontinuation: 18% bremelanotide vs 2% placebo discontinued due to adverse events.
  • Long-term safety / efficacy: Simon et al. 2019 Obstet Gynecol 134(5):909–917, PMID 31599847 — 52-week open-label extension; median ~25–27 lifetime injections; safety profile consistent with controlled phase.

Phase 2 / earlier — Female HSDD. Clayton AH et al. 2016 Women’s Health (Lond) 12(3):325–337 — Phase 2b dose-ranging RCT (0.75, 1.25, 1.75 mg SC) establishing the 1.75 mg dose; pooled 1.25/1.75 mg vs placebo significant on FSFI total (+3.6 vs +1.9, p=0.0017) and FSDS-DAO (–11.1 vs –6.8, p=0.0014). ⚠️ Industry-funded.

Abandoned intranasal Phase 2 — male ED programme.

  • Diamond LE et al. 2004 Int J Impot Res 16(1):51–59, PMID 14963471 — intranasal PT-141 in healthy men and mild-to-moderate ED; erectile response significant at doses >7 mg.
  • Rosen RC et al. 2004 Int J Impot Res 16(2):135–142, PMID 14999221 — subcutaneous PT-141 in healthy men and in Viagra-inadequate-responders; statistically significant erectile response at SC doses >1 mg in healthy men, and at 4 and 6 mg in Viagra-non-responders.
  • Safarinejad MR & Hosseini SY 2008 J Urol 179(3):1066–1071, PMID 18206919 — 342 sildenafil-non-responder men, intranasal bremelanotide 10 mg vs placebo; 33.5% vs 8.5% “positive clinical response” (p=0.03). An Expression of Concern was issued for this paper in January 2023 (PMID 36626345, J Urol 2023).
  • The Palatin intranasal-route ED programme was halted in 2007–2008 over a dose-dependent BP signal.

7.3 Observational / real-world evidence

  • FAERS post-marketing reports note nausea, BP elevations, focal hyperpigmentation, and rare hepatic enzyme elevations consistent with the single acute-hepatitis case described in the Vyleesi label open-label extension (transaminases >40× ULN, full resolution off-drug) [Regulatory document — FDA Vyleesi label §6.1; LiverTox NCBI Bookshelf NBK573221].
  • Real-world adherence and refill-persistence in commercial Vyleesi pharmacy claims is reported as low; quantitative figures derive from industry-cited internal pharmacovigilance and are not independently peer-reviewed.
  • Single-centre observational case series from sexual-medicine clinics (e.g., J Sex Med 2024 conference abstract 227) describe off-label SC bremelanotide use in men — descriptive uncontrolled retrospective reports only.

7.4 Trial registry / active programs

  • NCT02333071 (RECONNECT Study 301) — completed.
  • NCT02338960 (RECONNECT Study 302) — completed.
  • NCT06565611 (BMT-801 obesity Phase 2 with tirzepatide; readout 2025-03-31) ⚠️ Industry-funded. Phase 3 programme not publicly registered as of 2026-05-17.

7.5 Disputed Claims

Three disputes anchored in published or regulatory record; two additional disputes from the community layer are encoded in disputed_claims (tachyphylaxis; male non-responder rate).

Dispute 1 — Effect-size adequacy in RECONNECT (clinical meaningfulness). Position A (adequacy): FDA accepted the desire-and-distress co-primary structure as capturing the clinically relevant HSDD construct and approved on responder analyses, durability through 52-week OLE, and the unmet-need context for an on-demand non-hormonal pharmacotherapy. Position B (inadequacy): independent commentators note that FSFI-D between-group difference of ~0.30 on a 1.2–6.0 scale and FSDS-DAO Item 13 difference of ~0.30 on a 0–4 scale fall below conventionally cited minimum clinically important differences, that SSE numerically did not separate from placebo, and that 40% nausea and 18% all-cause discontinuation make the cost/benefit ratio contestable. Status: no resolution. Both positions present in the published record.

Dispute 2 — Cardiovascular safety: was the SC route truly safe enough? Position A: FDA accepted modest peak BP elevations (~2–6 mmHg SBP, ~3 mmHg DBP), transient, resolving within 12 h; label contraindication + dose-frequency cap judged sufficient risk management without REMS. Position B: the same compound at higher intranasal doses produced a BP signal sufficient to terminate the male-ED programme; trials excluded high-CV-risk subjects, so ambulatory BP data may understate real-world risk; the off-label-marketed-to population (men with ED, often older with comorbid hypertension or vascular disease) is precisely the population formally contraindicated. Status: no resolution. Off-label male use occurs in a population the SC programme did not study and the label specifically warns against.

Dispute 3 — Focal hyperpigmentation: manageable vs uncertain-reversibility with melanotan-II parallel. Position A: 1% incidence at ≤8 doses/month rising to 38% at daily ×8 days is mechanistically consistent with MC1R-mediated melanocyte stimulation and is the basis for the label’s monthly dose cap. Position B: “Resolution of the focal hyperpigmentation was not confirmed in all patients after discontinuation of VYLEESI” per the label. Melanotan-II case literature (a less MC-selective relative) describes persistent darkening of pre-existing naevi, new melanocytic lesions, and reports of melanoma diagnoses in heavy chronic users; off-label chronic use without the dose cap reintroduces this question. Status: no resolution; pharmacovigilance signal evolving.

7B. Community Evidence Layer

Community context

PT-141 carries ~22 years of continuous optimization-audience presence — among the longest of any peptide in the catalog — across three distinct adoption waves.

  • Wave 1 (~2003–2008): Palatin intranasal-spray era. Earliest references come from melanotan-II tanning users on bodybuilding forums (EliteFitness, MESO-Rx, AnabolicMinds) noticing spontaneous erections during melanotan cycles, and from people tracking Palatin’s Phase 2 intranasal PT-141 ED programme. Reference doses 7 mg and 20 mg intranasal still appear verbatim in old ExcelMale and EliteFitness threads. The 2008 hypertension-driven FDA clinical hold on intranasal PT-141 closed this wave.
  • Wave 2 (2019–2020): Vyleesi approval and the “female Viagra” framing. FDA approval (2019-06-21) reactivated community interest. The autoinjector’s ~$899 list price drove the audience immediately toward grey-market and compounded alternatives. Palatin’s 2020 mutual termination with AMAG and December 2023 sale of Vyleesi to Cosette for $12 million up-front + $159 million milestones (Fierce Pharma coverage) is the data point the community cites for “Vyleesi never lived up to the hype.”
  • Wave 3 (2020–2026): grey-market injectable phase. The dominant wave today. Subcommunities driving adoption: (a) men’s-health / TRT telehealth clinics (Defy Medical, Hone Health, Maximus, Tower Urology, Regenics, RebalanceMED, HydraMed, Wellcore, Renew Vitality, Limitless Male, Mott Haven, Texas Vitality), almost all listing PT-141 as a flagship libido offering; (b) bodybuilder/PED crossover crowd; (c) biohacker/longevity audience driven by Jay Campbell, Ben Greenfield, and the Huberman Lab episode 2024-04-01; (d) women’s sexual-wellness niche, perimenopausal/menopausal women routed through telehealth rather than via the FDA-labelled Vyleesi autoinjector.

Current trajectory (mid-2026): stable-to-rising in men’s-health telehealth; stable in the biohacker conversation; substantially disrupted on the grey-market side by the June 2025 FDA raid of Amino Asylum and the 2026-03-06 voluntary shutdown of Peptide Sciences. Community sources flag PT-141 as one of the peptides whose access pattern shifted hard between 2024 and 2026 — though Peptide Sciences PT-141 had a Finnrick A grade just before shutdown, so quality at that vendor was not the trigger.

Documented protocols

Convergence is striking: virtually every telehealth/clinic source lands on the Vyleesi-derived 1.75 mg SC, ≥45 min lead time, ≤8/month ceiling.

SourceDoseRouteFrequencyNotes
Vyleesi label (cited verbatim by HydraMed, Wellcore, Regenics, Hone Health)1.75 mgSC autoinjector≥45 min pre-activity; ≤1/24 h; ≤8/monthCanonical safety ceiling
Jay Campbell, jaycampbell.com0.5–1.0 mg → titrate to 1.5–2.0 mgSC2–3×/week; 48–72 h spacing”Most men respond best at 1.5–1.75 mg”
Maximus LOVER Protocol2 mg PT-141 + 5 mg tadalafilOral trocheDaily, not on-demandDeparture from on-demand framing
Defy Medical1.75 mg typicalSCOn-demand; ≥45 min pre-activityExplicit off-label male use
Renew Vitality2 mgSC2–3×/week; ≥24–36 h spacingNotes effects “last up to 72 h”; caps at 8/month
ExcelMale reconstitution guidance10 mg + 1 mL BAC = 10 mg/mL → start 0.5 mgSCOn-demand, self-titrated”Don’t exceed 500 mcg for first dose”
Valhalla Vitality triple compoundPT-141 1 mg + oxytocin 100 IU + tadalafil 10 mgOral troche / sublingualOn-demandSingle compounded product
ExcelMale microdosing outlier15–20 mcg × 5 daily microdosesSCDaily, dividedSingle user; claimed superior to single large doses
Formulate Rx / Inner Balance”Customizable” (Palatin-era 7–20 mg range)Compounded intranasalOn-demandRoute Palatin abandoned in 2008

Claimed effects

  • Increased libido / sexual desire (both sexes) — widespread; every source surveyed.
  • “Spontaneous arousal” / desire-driven framing — widespread (Huberman Lab; Greenfield/Campbell via Dexa.ai).
  • Erection quality / on-demand erections in men (off-label) — widespread in men’s-health channel.
  • “Spontaneous rock-hard erections for 24 hours” first-use outlier — single-source honeymoon-effect reports.
  • Faster refractory period — common in biohacker write-ups.
  • Energy / mood lift, mild euphoria — occasional.
  • Spontaneous arousal in women / increased subjective desire — common (Vyleesi-aligned).
  • Recreational / party-drug use (“the sex drug”) — occasional, mostly bodybuilding-forum framing.
  • Tanning / skin-darkening side-benefit (residual from melanotan lineage) — occasional, almost always framed as side effect not benefit.
  • Non-response (~40% of men) — common counter-claim (Jay Campbell aggregated via Greenfield).

Reported side effects

  • Nausea — universal; “the nausea peptide.” ExcelMale anecdote: “the 4th time I used it, I was toilet hugging for better than a day.” Drugs.com community-summary frequency: 40% vs 1% placebo. EliteFitness vendor advice: “take Benadryl pre-consumption.”
  • Facial flushing — widespread; ~20.3%.
  • Transient BP spike — widespread concern-level, occasional felt-level; ~1% of trial subjects had readings ≥180/110.
  • Hyperpigmentation / freckling / mole-darkening / “PT-141 face” — common as a concern; occasional as a reported lived experience; Koniver via Huberman Lab: “unnatural orange-tinted tanning effect.”
  • Priapism / sustained erection (men, with PDE5i co-use) — occasional; flagged on every clinic page. IPS recommends against PT-141 + PDE5i in men due to hypertension/priapism risk.
  • Headache — widespread; mild–severe; ExcelMale: “skull-crusher … 400–600 mg ibuprofen 2–3×/day.”
  • Body aches / myalgia — occasional.
  • Decreased appetite — occasional; consistent with MC4R mechanism.
  • Prolonged nausea (“works for 12 h but I’m nauseated for 8”) — common qualitative pattern.
  • Injection-site reactions — common; ~13.2%.
  • Anhedonic-depression concern (chronic, theoretical) — single-source ExcelMale caution; not corroborated.
  • Tachyphylaxis / loss of magic — occasional; single ExcelMale “holy grail wore off” arc is the most-cited anecdote.

Community dissent

The PT-141 community is internally split on several axes.

  1. Does it actually work — and for whom? Jay Campbell, Ben Greenfield, and most men’s-health clinics describe response as common and dramatic; the same Greenfield/Campbell discussion (per Dexa.ai aggregation) notes ~40% non-responder rate in men. No consensus on whether non-response is biological variance, dose-too-low, or expectation effect.
  2. Vyleesi commercial-failure narrative. Community framing crystallizes around three theories (FDA label too narrow; CV warning killed prescriber comfort; price killed it); most threads end with “all three.”
  3. Men using a drug FDA-approved for women — off-label legitimacy. Almost every men’s-health clinic acknowledges off-label status explicitly. Biohacker camp treats this as a non-issue. A subset of women’s-health voices express discomfort at men dominating community PT-141 discussion when the drug was FDA-cleared on women’s pivotal-trial data.
  4. Hyperpigmentation — real and important, or overblown? Drugs.com–compiled Phase-3 data: 1% under label-compliant dosing vs 38% under daily-for-8-days. Concerned camp (Koniver/Huberman; ExcelMale melanotan-II veterans); dismissive camp (clinic pages noting “usually reversible” — though the label itself says it may persist); skin-tone-stratified concern flagged consistently.
  5. Tachyphylaxis debate. Unresolved; no clinical-trial data referenced by the community resolves it.
  6. Recreational vs medical positioning. EliteFitness vendor framing at one pole; Defy Medical / Wellcore at the other. Medical positioning dominates 2024–2026; recreational framing more visible in older bodybuilding-forum archives.

Stack patterns

  • PT-141 + tadalafil or sildenafil (the “desire + erection” stack). Most-discussed pairing. Maximus’ LOVER Protocol bundles PT-141 + tadalafil. ExcelMale users routinely combine 1.75 mg PT-141 with 25–50 mg sildenafil or 5–10 mg tadalafil. IPS guidance via Northampton Integrative Medicine: do not combine in men due to additive hypertension and priapism risk. Telehealth-clinic space sells the stack anyway (Valhalla Vitality triple compound, Beyond MD, Limitless Male).
  • PT-141 + oxytocin (the “intimacy stack”). Heavily marketed by compounders: Peptide Works’ “PT-141 Oxytocin Nasal Stack,” Elevation Wellness’ “Super Sexy Stack,” Pretty Peptide UK’s “INTIMUS.” Mechanistic rationale (PT-141 raising endogenous oxytocin) is preclinical-only.
  • PT-141 + kisspeptin-10 (emerging libido stack). Sold by Peptide Works, Direct Peptides; framed by Jay Campbell as combining hormonal regulation with central arousal. Emerging, not yet codified.
  • PT-141 + melanotan-II (tan + libido stack). Bodybuilder-forum heritage (EliteFitness, MESO-Rx archives). Community consistently flags MC1R overlap risk — both compounds drive hyperpigmentation; cumulative dosing concerns compound. Not currently promoted by any reputable clinic; modern biohacker write-ups explicitly warn against co-use.
  • PT-141 with TRT context. Dominant clinical-channel use; most men’s-health clinics offering PT-141 primarily serve a TRT patient base. Framing: testosterone restores hormonal substrate; PT-141 adds on-demand central arousal when libido remains low despite optimised total/free T.
  • Women’s stack: PT-141 + low-dose testosterone for HSDD (especially post-menopausal). Hone Health’s women’s page explicitly markets the combination for perimenopause/menopause; positioned as the workaround for Vyleesi’s premenopausal-only label.
  • PT-141 + tadalafil + oxytocin (triple). Valhalla Vitality 1 mg + 100 IU + 10 mg as a single compounded product; Beyond MD and Limitless Male offer functionally equivalent combinations.

Vendor / supply context

PT-141 has a visible grey-market and compounded-supply footprint, but the reliability of non-branded supply is uneven. The 2024–2026 period saw material disruption across the peptide-vendor ecosystem, including warning-letter activity, vendor exits, and enforcement actions. These events matter editorially because they affect the interpretability of community reports: a reported benefit or adverse effect may reflect bremelanotide exposure, product concentration error, impurity profile, route, co-use, or expectation effects.

The FDA-approved Vyleesi autoinjector is the only product with NDA-grade chain-of-custody controls. Compounded and research-use supply should be treated as a distinct evidence context rather than merged with the clinical-trial safety record.

Community Score / Tier

DimensionScoreRationale
Usage volume20/25~25 named telehealth/clinic product pages; every major peptide-education site; multiple bodybuilding forums with archive threads back to ~2015; named Huberman Lab episode (2024-04-01); routine offering in FDA-Vyleesi commercial channel. Held back from full marks by Reddit retrieval limitations and no PT-141 wiki of the scale that exists for BPC-157 or GLP-1s.
Protocol codification22/25Vyleesi-derived 1.75 mg SC, ≥45 min pre-activity, ≤1/24 h, ≤8/month is almost universally adopted across telehealth clinics, biohacker write-ups, and forum FAQs. Variations (Maximus oral troche daily; bodybuilder microdosing) are clearly identified as departures from a recognised canonical baseline.
Reported effect consistency17/25Signal — increased libido and arousal with strong nausea — is recognisable and reported by most users. Brought down by (a) ~40% non-responder rate in men (Jay Campbell / Greenfield); (b) tolerability profile heavy enough that 8% of clinical-trial users discontinued specifically for nausea.
Time in circulation21/25Continuous community presence from Palatin nasal-spray era (~2003) through 2008 hypertension hold, 2019 FDA approval, 2020–2026 grey-market injectable phase. ~22 years. Held back from full marks by uneven coverage between waves.
Total80/100Tier A (75–89)

8. Safety Profile

Common adverse events

From Phase 3 RECONNECT pooled placebo-controlled data per the FDA Vyleesi label:

Adverse reactionBremelanotide (n=627)Placebo (n=620)
Nausea40.0%1.3%
Flushing20.3%0.3%
Injection-site reactions13.2%8.4%
Headache11.3%1.9%
Vomiting4.8%0.2%
Cough3.3%1.3%
Fatigue3.2%0.5%
Hot flush2.7%0.2%
Paraesthesia2.6%0.0%
Dizziness2.2%0.5%
Nasal congestion2.1%0.5%

[Regulatory document — FDA Vyleesi label Table 1, §6.1]

Nausea: antiemetic required in 13% of bremelanotide subjects; discontinuation for nausea in 8%; median onset within 1 h, duration ~2 h; highest incidence after first dose (21%), declining to ~3% on subsequent doses.

Serious or theoretical risks

  • Transient BP rise / HR decrease: peak SBP +6 mmHg, DBP +3 mmHg at 2–4 h; HR –5 bpm; resolution within 12 h. Contraindicated in uncontrolled hypertension or known cardiovascular disease.
  • Focal hyperpigmentation: 1% at on-label dosing; 38% at daily ×8 days; higher risk in darker skin; involvement reported on face, gingiva, and breasts; not always reversible on discontinuation.
  • Acute hepatitis (single case): one subject in the open-label extension with transaminases >40× ULN, total bilirubin 6× ULN; resolution 4 months after discontinuation; causality not definitively established.

Trial exclusions / special populations

  • Pregnancy: animal reproduction data show fetal harm in dogs and mice at exposures ≥16× and ≥125× human AUC; pregnancy registry maintained. Effective contraception advised.
  • Lactation: no human data; not recommended.
  • Pediatric / geriatric: not established.
  • Renal / hepatic impairment: no adjustment in mild/moderate; caution in severe.
  • Postmenopausal women: excluded from RECONNECT; community use in this population (perimenopausal/menopausal HSDD via telehealth) is outside the Phase 3 evidence base.

Community-reported adverse signals

  • “Skull-crusher” headaches the day after — common; ibuprofen 400–600 mg 2–3×/day reported as insufficient relief.
  • Prolonged nausea (24 h+) — pattern reported in ExcelMale; outside the median 2 h duration documented in trials.
  • “PT-141 face” / orange-tinted tanning — Koniver via Huberman Lab.
  • Anhedonic-depression concern — single ExcelMale caution; not corroborated.

Pharmacovigilance / regulatory safety communications

  • Retraction status of cited studies: Safarinejad & Hosseini 2008 (J Urol; intranasal bremelanotide in sildenafil-non-responders) is the subject of a published Expression of Concern [PMID 36626345, J Urol 2023]. Any downstream secondary-literature use of this study must report the EoC explicitly.
  • FAERS post-marketing: nausea, BP elevations, focal hyperpigmentation, rare hepatic enzyme elevations.

9. Drug Interactions

  • Naltrexone (oral): bremelanotide significantly decreases systemic exposure of orally administered naltrexone. Vyleesi label instructs avoidance with oral naltrexone for alcohol-use or opioid-use disorder because of the severe consequence of naltrexone treatment failure [Regulatory document — FDA Vyleesi label §7.2].
  • Other oral drugs: bremelanotide slows gastric emptying and may reduce rate/extent of absorption of concomitant oral drugs; specific counsel against concomitant antibiotics dependent on threshold concentrations, and notes that delayed onset may affect rapid-action oral drugs (e.g., indomethacin) [Regulatory document — FDA Vyleesi label §7.1].
  • PDE5 inhibitors: no formal interaction study in the Vyleesi NDA. Earlier Phase 2 co-administration data (Diamond/Rosen) demonstrated additive erectile response in men; potential additive cardiovascular effects from BP-modulating combinations are not formally characterised at SC label dose. Practitioner guidance cited in the community layer warns against co-use in men because of additive hypertension and priapism risk.
  • Alcohol: dedicated interaction study using intranasal 20 mg bremelanotide + 0.6 g/kg ethanol found no clinically significant interaction at that intranasal dose; SC 1.75 mg label has no alcohol restriction.
  • Oxytocin (compounded): no formal interaction study. The community/compounding rationale cites preclinical evidence that PT-141 activates endogenous oxytocin via MC4R/PVN; exogenous oxytocin on top is unstudied as a combination at PT-141 label dose.
  • Melanotan-II: no formal interaction study; community-flagged additive MC1R hyperpigmentation risk.

10. Research Gaps

  • No adequately powered Phase 3 trial in male sexual dysfunction. The only randomised data in men involve the discontinued intranasal route or are flagged with an Expression of Concern.
  • No long-term controlled safety data beyond 52 weeks. Off-label chronic exposure (multi-year compounded SC use) is uncharacterised.
  • No head-to-head trial vs flibanserin in HSDD, despite both being FDA-approved for the same population.
  • No mechanism-of-action clarification for the desire vs arousal distinction in humans (label explicitly states mechanism is unknown).
  • No prospective study addressing reversibility of focal hyperpigmentation in chronic users.
  • No data in postmenopausal women in a controlled Phase 3 setting (RECONNECT excluded postmenopausal women).
  • No completed Phase 3 obesity data with bremelanotide despite the recent Palatin BMT-801 + tirzepatide Phase 2 readout (industry-funded, not peer-reviewed).
  • No anti-doping prevalence study; the actual frequency of bremelanotide use among athlete populations is not characterised.
  • No controlled study of PT-141 + PDE5i combination cardiovascular safety in older men with comorbid hypertension/vascular disease — the off-label-marketed population.

11. Bottom-Line Encyclopedia Note

PT-141 / bremelanotide (Vyleesi, NDA 210557, 2019-06-21) is the only FDA-approved central-acting on-demand pharmacotherapy for acquired generalised hypoactive sexual desire disorder in premenopausal women. Two pivotal Phase 3 RECONNECT trials demonstrated statistically significant but small-magnitude improvements on FSFI-Desire and FSDS-DAO co-primary endpoints versus placebo, set against a 40% nausea burden and 18% all-cause discontinuation. Approval is jurisdictionally narrow — FDA only; not EMA, not other major regulators. The optimization-audience use case — male sexual function via compounded subcutaneous injection or intranasal spray — is not supported by completed Phase 3 trials. The only randomised male data come from the abandoned intranasal-route ED programme (Diamond 2004, Rosen 2004) and from a single sildenafil-non-responder trial (Safarinejad 2008) now flagged with an Expression of Concern. Same molecule; same dose; different evidence by indication.

11B. Gap Analysis - Where Science and Community Diverge

Pattern cell: High community + Low science (for the community-dominant claim) → FDA approval halo over thin general-use case, with indication divergence.

PT-141 sits in the same gap cell as SS-31 (Forzinity approved for Barth syndrome, community uses for longevity) and Ipamorelin (Phase 2 POI tested negative, community uses for body composition). The structural pattern is: the science is real and meaningful, but for one narrow indication the optimization community largely does not use; the community-dominant use case is a different indication that has either not been tested adequately in humans or was tested under conditions (abandoned route, EoC-flagged paper) that do not support it.

Specific gaps:

  1. The flagship community claim (male libido / on-demand male sexual function) has no completed Phase 3 trial. The Phase 2 intranasal programme was abandoned in 2008 over a BP signal. Diamond 2004 and Rosen 2004 are pharmacodynamic dose-finding in healthy volunteers and Viagra-non-responders, not pivotal efficacy trials. Safarinejad 2008 — the most-cited “positive male trial” in clinic marketing and biohacker literature — carries a published Expression of Concern (2023). The community treats bremelanotide-for-men as a settled product; the regulatory record treats it as untested.

  2. The community-dominant indication (male libido) and the FDA-approved indication (premenopausal HSDD) use the same dose. This is the structurally important difference from SS-31 and Ipamorelin, both of which have a research-dose : community-dose ratio of roughly 10× or 30×. For PT-141 the ratio is ~1:1 — community SC dose is the label SC dose. Community “no response in men” complaints are therefore not explained by under-dosing (as they would be for ipamorelin); they require receptor-level, sex-difference, or expectation-effect explanations the literature has not generated. The ~40% non-responder rate (Jay Campbell aggregated via Greenfield) sits inside this unresolved space.

  3. Route divergence carries hidden safety history. Three routes circulate: SC (FDA-approved), compounded intranasal (Palatin abandoned 2008 for safety), and oral troche / sublingual (Maximus, Valhalla Vitality — no published bioavailability). The intranasal route was specifically discarded by the originator over a dose-dependent BP signal at the higher intranasal doses required to overcome variable absorption. Community framing of “compounded intranasal spray” as a convenience alternative to SC obscures this route-specific cardiovascular history. Mirror flag in route_profiles (intranasal evidence_tier E, not equivalent to SC).

  4. Off-label male use occurs in a population the label specifically contraindicates. Vyleesi is contraindicated in uncontrolled hypertension or known CV disease. The off-label-marketed population (men with ED, often older with comorbid hypertension or vascular disease) is precisely this population. The Phase 3 trial excluded high-CV-risk subjects, so ambulatory BP data may understate real-world risk in the off-label-use population.

  5. Identity confusion with melanotan-II is structurally consequential, not cosmetic. Melanotan-II case literature documents persistent naevus darkening, new melanocytic lesions, and melanoma diagnoses in heavy chronic users. Bremelanotide is the more receptor-selective relative, but at on-label dose-capped exposure only. Off-label chronic use (multi-year compounded SC, exceeding the 8/month ceiling) re-introduces the melanotan-II-style chronic-MC1R-exposure question, which has not been formally studied because the FDA-approved use is on-demand and dose-capped. Community channels that treat the molecules as interchangeable are losing this distinction.

  6. Stack patterns codify combinations the IPS warns against. PT-141 + PDE5i (tadalafil or sildenafil) is the most-discussed stack; Maximus’ LOVER Protocol bundles it as a single product. The International Peptide Society (per Northampton Integrative Medicine) recommends against the combination in men due to additive hypertension and priapism risk. The community routinely sells what the practitioner-society guidance warns against — a separate failure mode from the bremelanotide-vs-melanotan-II identity confusion.

Compared with anchors: PT-141’s amplitude (Community 80, Science 20 for the primary claim → 60-point gap) is intermediate between SS-31 (Community 56, Science 8 for longevity → 48-point gap) and BPC-157 (Community A, Science D → ~78-point gap). The pattern is structurally closer to SS-31 (real narrow regulatory anchor, community transfers inference to an untested indication) than to BPC-157 (no approval, single-group dependency 🔴). Unlike Ipamorelin, PT-141’s dose is not the limiting factor — making the male non-responder question a sharper open scientific question than the analogous ipamorelin question.

12. Three Paths

Conservative path

Gates: completed and replicated Phase 3 RCT in male sexual dysfunction with a placebo control and adequately powered safety analysis in the off-label-marketed population (men with comorbid hypertension/vascular disease); independent peer-reviewed replication of the Safarinejad 2008 finding without the data-integrity concerns that produced the 2023 Expression of Concern; long-term controlled safety data on focal hyperpigmentation reversibility under chronic exposure outside the 8/month label cap; head-to-head trial vs flibanserin in HSDD. None of these gates is currently met for the off-label use case. The conservative path therefore declines off-label male use pending the BMT-801 Phase 3 readout and any future male-sexual-function programme. For premenopausal HSDD, the conservative path treats Vyleesi as approved with a 40% nausea / 18% discontinuation cost-benefit explicit in the decision.

Moderate path

Treats PT-141 at its current Tier (Science C / Community A for off-label male use; Science A / Community B for premenopausal HSDD) with monitoring. For on-label use (premenopausal HSDD): Vyleesi prescribed via FDA pathway, with Cosette patient-assistance for cost, under the label’s 8/month cap, with documented CV screening. For off-label male use (population that meets label contraindications excluded): physician-supervised SC at the Vyleesi-derived 1.75 mg dose, ≥45 min lead time, ≤1/24 h, ≤8/month ceiling; baseline ambulatory BP monitoring before starting; CV screening including resting BP, HR, history; bloodwork at baseline and at 3-month follow-up (CBC, CMP, LFTs given the single-case acute-hepatitis signal); skin examination at baseline and 6 months for hyperpigmentation tracking. No PDE5i co-administration. Vendor selection restricted to FDA-approved Vyleesi via Cosette where available, or to a single 503A compounding pharmacy with documented sterile-product practice and per-batch certificate-of-analysis. Discontinuation triggers: persistent BP rise, focal hyperpigmentation in skin areas the patient cares about, new naevus changes, refractory nausea, lack of response after appropriate trial.

High-tolerance path

Acknowledges no conservative gates are met for off-label male use. Multi-year compounded SC use at the Vyleesi-derived 1.75–2 mg dose; some users above the 8/month cap; some users via compounded intranasal (the route Palatin abandoned for safety); some users on stacked PT-141 + PDE5i protocols sold by telehealth compounders despite IPS guidance against. Mitigation in the community currently codifies: vendor selection with Janoshik or ChemClarity per-batch COA (BioLongevity Labs, current Peptide Sciences successors, Cosmic Peptides where available); reconstitution standard 10 mg + 1 mL BAC = 10 mg/mL with 0.5 mg first dose; antiemetic pre-medication (ondansetron clinic-prescribed, Benadryl forum-prescribed); ambulatory BP monitoring (the population at highest off-label risk overlaps the population most likely to have a home BP cuff); structured logging of dose, response, AE pattern; skin photography for hyperpigmentation tracking. Stack co-administration with PDE5i remains common despite IPS guidance against; the high-tolerance path accepts this as practice while flagging it as the highest-amplitude unresolved community-science gap. Physician dialogue strongly advised; declare to any clinician managing concurrent CV therapy or TRT.

The three paths are definitions of practice, not recommendations.

13. Key References

Science layer

Regulatory documents.

  1. FDA NDA 210557, Vyleesi approval letter, 2019-06-21.
  2. FDA Vyleesi Prescribing Information, initial approval 2019, current revision 6/2019.
  3. FDA Vyleesi Multidisciplinary Review (NDA 210557Orig1s000).
  4. FDA Risk Assessment Memorandum, NDA 210557.
  5. FDA PCAC meeting agendas, 2024-10-29 and 2024-12-04 (bremelanotide not on agenda).
  6. TGA Therapeutic Goods (Poisons Standard — October 2025) Instrument 2025.
  7. WADA 2026 Prohibited List, in force 2026-01-01.
  8. WADA 2026 Monitoring Program.
  9. DoD OPSS ingredient guidance, accessed 2026-05-17.
  10. NCAA banned-drug classes 2025–26.

Peer-reviewed Phase 3 — Female HSDD.

  1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019;134(5):899–908. PMID 31599840. ⚠️ Industry-funded.
  2. Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019;134(5):909–917. PMID 31599847. ⚠️
  3. Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt) 2022. ⚠️

Peer-reviewed Phase 2 / earlier — Female HSDD.

  1. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 2016;12(3):325–337. ⚠️
  2. Althof S, Derogatis LR, Greenberg S, et al. Responder analyses from a Phase 2b dose-ranging study of bremelanotide. J Sex Med 2019;16:1226–1235. ⚠️
  3. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). J Sex Med 2006;3(4):628–638. PMID 16839319. ⚠️

Peer-reviewed — male sexual function (intranasal programme).

  1. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141. Int J Impot Res 2004;16(1):51–59. PMID 14963471. ⚠️
  2. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141. Int J Impot Res 2004;16(2):135–142. PMID 14999221. ⚠️
  3. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008;179(3):1066–1071. PMID 18206919. Expression of Concern: PMID 36626345 (J Urol 2023).

Peer-reviewed mechanistic / preclinical.

  1. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. PNAS 2004;101(27):10201–10204.
  2. Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med 2007;4 Suppl 4:269–279.
  3. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003;994:96–102. ⚠️
  4. Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides 2005;26:1687.
  5. Hadley ME, Hruby VJ, Blanchard J, et al. Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharm Biotechnol 1998;11:575–595.
  6. Argiolas A, Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol 2005. 🔴

Systematic review / meta-analysis (non-Cochrane).

  1. Anand M, et al. Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-analysis of Treatment Options. PubMed 2025. PMID 40543759.

Drug-reference and academic secondary.

  1. PubChem CID 9941379 (bremelanotide).
  2. IUPHAR/BPS Guide to PHARMACOLOGY — melanocortin receptor family pages.
  3. LiverTox: bremelanotide. NCBI Bookshelf NBK573221.

Clinical trial registry.

  1. NCT02333071 (RECONNECT Study 301).
  2. NCT02338960 (RECONNECT Study 302).
  3. NCT06565611 (BMT-801 obesity Phase 2 with tirzepatide; readout 2025-03-31). ⚠️ Industry-funded.

Industry / press releases (flagged).

  1. Palatin Technologies press release, FDA Approves Vyleesi, 2019-06-21. ⚠️
  2. Palatin Technologies press release, BMT-801 Phase 2 obesity co-administration study primary endpoint, 2025-03-31. ⚠️
  3. Palatin Technologies press release, AMAG mutual termination, 2020-07-27. ⚠️
  4. Palatin Technologies press release, Cosette sale of Vyleesi ($12M up-front + $159M milestones), 2023-12-20. ⚠️

Community layer

  1. ExcelMale forum thread, “The Amazing Bremelanotide PT-141 (Vyleesi).” Ongoing.
  2. ExcelMale forum thread, “PT-141 — Bremelanotide.” Ongoing.
  3. ExcelMale forum thread, “A different dosing strategy with bremelanotide (PT-141) yields dramatically better results.” Ongoing.
  4. ExcelMale forum thread, “PT-141 (Bremelanotide) for Improved Sex Drive and Erections.” Ongoing.
  5. EliteFitness forum thread, “PT-141 (Bremelanotide) 10mg.”
  6. Huberman Lab podcast, “Benefits & Risks of Peptide Therapeutics for Physical & Mental Health.” 2024-04-01. PT-141 segment ~01:12:09.
  7. Huberman Lab podcast, “Dr. Craig Koniver: Peptide & Hormone Therapies.” 2024-10-07.
  8. Jay Campbell, “How to Use PT-141 Peptide: Dosage and Frequency Protocol.” jaycampbell.com, updated 2024–2025.
  9. Jay Campbell, “Peptide Therapy for Men.” jaycampbell.com.
  10. Jay Campbell, “The Best 4 Peptides For Libido.” jaycampbell.com.
  11. Ben Greenfield × Jay Campbell joint discussion, summarised on Dexa.ai.
  12. Maximus, “LOVER Protocol” — maximustribe.com PT-141 dosage chart.
  13. Defy Medical, “Peptides: Bremelanotide (PT-141)” clinic monograph.
  14. Hone Health, “PT-141 Peptide: The Libido Drug for Men and Women.”
  15. Hone Health women’s and men’s PT-141 product pages.
  16. Renew Vitality (vitalityhrt.com) PT-141 protocol page.
  17. HydraMed, Wellcore, Regenics, Limitless Male, Mott Haven Medical Center, Texas Vitality, RebalanceMED, Concierge MD LA, medAge, Inner Balance, Amazing Meds, RevitalyzeMD, Valhalla Vitality clinic pages.
  18. Tower Urology PT-141 page, Los Angeles.
  19. Formulate Rx and Inner Balance compounded intranasal product pages.
  20. Northampton Integrative Medicine PT-141 monograph (cites IPS guidance against PDE5i co-use).
  21. Swiss Chems PT-141 10 mg product page (swisschems.is and swisschems.org).
  22. Peptide Sciences PT-141 10 mg product page (peptidesciences.com, cached pre-shutdown).
  23. Ameano Peptides PT-141 product page.
  24. Peptomed PT-141 10 mg product page (peptomed.pl).
  25. Real Peptides “Is Swiss Chems Legit Review 2026.”
  26. Muscle and Brawn “Peptide Sciences Shut Down” — Finnrick A grade for PT-141 from Peptide Sciences; Amino Asylum June 2025 raid timeline.
  27. BioStrata Research “What Happened to Peptide Sciences” — 2026-03-06 voluntary shutdown.
  28. The Peptide Catalog “Amino Asylum Shut Down” and “Why Peptide Sciences Really Shut Down.”
  29. PeptidesExplorer “Peptide Sciences Shutdown Explained.”
  30. The Peptide Report “Amino Asylum Review.”
  31. PSPeptides “What Happened to Amino Asylum.”
  32. TitrateLab “The Peptide Vendor Graveyard.”
  33. PeptideLaws.com “Why Did Peptide Sciences Shut Down?”
  34. Grokipedia “Amino Asylum” — Soma Chems rebrand.
  35. Fast Life Hacks “Andrew Huberman’s Peptide List.”
  36. Bremelanotide Wikipedia entry.
  37. Anthony Campbell PharmD, “Reversing the Curse of Aging” (LinkedIn long-form) — Palatin-era intranasal 7 mg / 20 mg dose-range community-archived data.
  38. Fierce Pharma “Palatin sells female libido drug Vyleesi to Cosette.”

14. Audit / Refresh Trail

  • Composed: 2026-05-19
  • Pass 1 file: pt-141_sci_2026-05-17_C20_md.md — Pass 1 deep research, separate chat, 2026-05-17. Primary claim filename score: C/20 (male sexual function, off-label optimization use). Sanity check: female HSDD A/65 (FDA-approved indication).
  • Pass 2 file: pt-141_com_2026-05-17_A80_m.md — Pass 2 deep research, separate chat, 2026-05-17. Community Score A/80 (global, dominated by off-label male use).
  • Last regulatory review: 2026-05-17.
  • Last community review: 2026-05-17.
  • Next refresh due: 2026-11-19.
  • Refresh triggers:
    • BMT-801 Phase 2 obesity (PT-141 + tirzepatide) full peer-reviewed publication or Phase 3 programme announcement.
    • Any further FDA enforcement action against grey-market peptide vendors stocking PT-141 (Swiss Chems warning-letter trajectory, FDA action against Soma Chems / Amino Asylum successor brands).
    • Any retraction (vs current Expression of Concern) of Safarinejad 2008.
    • WADA 2027 Prohibited List for explicit naming of bremelanotide.
    • Cosette commercial trajectory of Vyleesi (next public Palatin filing or Cosette quarterly statement).
    • EMA action on HSDD pharmacotherapy class (no EMA-approved option exists as of 2026-05-17).
    • Any independent Western RCT in male sexual dysfunction with bremelanotide.
    • TGA scheduling change at 6-monthly Poisons Standard update.
    • Major Huberman Lab / Peter Attia / Joe Rogan PT-141-specific episode at primary-transcript resolution.
  • Identity calibration status: two-molecule confusion (PT-141 ≠ melanotan-II) and route-changes-claim (intranasal abandoned vs SC approved vs oral troche unstudied) flagged in identity_warnings; mirrored in body Identity Calibration section.
  • Calibration anchors used:
    • Primary: SS-31 — ss-31_mono_2026-05-15_D08-C56.md — FDA approval halo over thin general-use case pattern. Vyleesi approved for premenopausal HSDD; community uses for male libido. SS-31 approved for Barth syndrome; community uses for longevity. Same structural pattern.
    • Secondary: Ipamorelin — ipamorelin_mono_2026-05-18_D10-A80.md — Indication divergence pattern. Phase 2 POI tested negative, community uses for body composition. PT-141 has FSAD/men ED programs that failed or were halted, community uses for male libido.
    • Tertiary: Semaglutide / Tirzepatide — semaglutide_mono_2026-05-13_S95-C92.md and tirzepatide_mono_2026-05-13_S95-C81.md — approved-drug regulatory framing for the FDA-approved indication (premenopausal HSDD) science section.
  • Gap-matrix subclass assignment: “High community + Low science: FDA approval halo over thin general-use case” + “indication divergence” (per v5 anchor table; subclass stack with SS-31 and Ipamorelin).
  • Dose-ratio finding: research dose : community dose ratio is ~1:1 for the off-label male use case (community uses Vyleesi label dose, 1.75–2 mg SC). Structurally different from SS-31 (~10× gap) and Ipamorelin (~10× gap). This rules out under-dosing as the explanation for the ~40% male non-responder rate.
  • Structured fields left needs_review: true: claim_profiles[obesity_weight_loss].needs_review: true (pending BMT-801 full publication).
  • Community-only signals not in regulated trials: “skull-crusher” day-after headaches; prolonged nausea (24 h+) outside the trial-documented 2 h median duration; anhedonic-depression concern (single-source ExcelMale caution, not corroborated); tachyphylaxis arc (single ExcelMale “holy grail wore off” anecdote).
  • Single-group dependencies 🔴: Cagliari group (Argiolas / Melis / Sanna / Succu) for peripheral-cascade specifics of male erectile pathway preclinical mechanism. Pivotal Phase 3 data (Kingsberg 2019, Simon 2019, RECONNECT 301/302) is industry-funded ⚠️ but is two-trial replicated in-house, not single-group in the BPC-157 / Epitalon sense.